COMPANY OVERVIEW

KaNDy Therapeutics is a clinical-stage company focused on optimizing the potential of NT-814 in the treatment of common, chronic debilitating female sex-hormone related conditions.

---

LOCATION

Stevenage, England, UK

---

THERAPEUTIC AREAS

Women's Health

---

WEBSITE

https://www.kandytherapeutics.com

---

CAREER WEBSITE

None

---

SOCIAL MEDIA

---

INVESTORS

---

---

PRESS RELEASES

Aug 11, 2020

Bayer to Acquire UK-Based Biotech KaNDy Therapeutics Ltd.

Aug 11, 2020

Advent Life Sciences announces sale of its portfolio Company KaNDy Therapeutics to Bayer AG for USD 425M upfront plus USD 450M in potential development milestones followed by further potential commercial milestones

Jan 13, 2020

KaNDy Therapeutics Announces Positive Phase 2b Data in Post-Menopausal Women with its Lead Non-Hormonal Product NT-814

Jan 7, 2019

KaNDy Therapeutics announces the appointment of Andrew Kay as Independent Chairman of the Board

Dec 11, 2018

KaNDy Therapeutics announces initiation of Phase 2b trial of NT-814 for the treatment of troublesome post-menopausal symptoms

For More Press Releases

---